

Guidelines for the Blood Transfusion Services

Updates to the Red Book

<http://www.transfusionguidelines.org/red-book/latest-updates>

Updates to the Red Book

2026

01 May	CN 10-2026	Changes to be implemented on the new JPAC website
17 February	CN 04-2026	3.4: Informed consent
17 February	CN 03-2026	23: Specification for the uniform labelling of blood, blood components and blood donor samples
17 February	CN 02-2026	Chapter 7, Annexes 3 and 5 - Removal of vCJD risk from component labels

2025

08 December	CN 38-2025	A3.5: Red Cells for Neonates and Infants, Leucocyte Depleted, Washed
07 August	CN 25-2025	7.2.1: Red Cells and Plasma, Leucocyte Depleted A4.6: Whole Blood, Leucocyte Depleted
24 July	CN 24-2025	A3.12: Platelets, Apheresis, in Additive Solution and Plasma, Leucocyte Depleted
24 July	CN 23-2025	A3.11: Dried Plasma, Leucocyte Depleted
18 July	CN 14-2025	3.4.1: Use of third-party interpreters
23 May	CN 11-2025	9.3: Specific screening targets Annexe 1: NIBSC standards available from MHRA
30 April	CN 10-2025	3.16: Autologous donations 3.17: References
28 February	CN 04-2025	4.2: Staffing and training principles for donation sessions 4.3: Clinical leadership at donor sessions 4.7: Equipment and consumables 4.9: References
24 January	CN 02-2025	7.5.7: Human Plasma for Fractionation, Cryoprecipitate Depleted, Leucocyte Depleted

2024

07 October	CN 28-2024	5.10: Staffing and training principles for donation sessions 5.13: Clinical leadership at donor sessions Chapter 5, Appendix I - Serious Adverse Events of Donation (removed)
17 May	CN 29-2024	7.5.6: Human Plasma for Fractionation, Leucocyte Depleted

18 April	<u>CN 05-2024</u>	Chapter 21: Tissue banking: tissue retrieval and processing Annexe 7: Requirements for the timing of testing for Hematopoietic Progenitor Cells (HPCs)
13 March	<u>CN 03-2024</u>	Chapter 2: Quality in blood and tissue establishments and hospital blood banks Chapter 6: Evaluation and manufacture of blood components Chapter 7: Specifications for blood components Annexe 3: Provisional Components Annexe 4: Redundant Components Annexe 5: Blood Components for Contingency Use

2023

11 December	<u>CN 40-2023</u>	7.31: Irradiated components 9.2: Microbiology screening 9.3: Specific screening targets 9.4: Reinstatement of blood donors 9.7: Recommended standards for environmental monitoring (EM) of processing facilities
02 November	<u>CN 39-2023</u>	Annexe 7: Requirements for the timing of testing for HPCs
04 September	<u>CN 16-2023</u>	Chapter 4: Premises and quality assurance at blood donor sessions Chapter 5: Collection of a blood or component donation Chapter 11: Reagent manufacture Chapter 12: Donation testing (red cell immunohaematology) Chapter 13: Patient testing (red cell immunohaematology) Chapter 14: Guidelines for the use of DNA/PCR techniques in Blood Establishments Chapter 15: Molecular typing for red cell antigens Chapter 16: HLA typing and HLA serology Chapter 17: Granulocyte immunology Chapter 18: Platelet immunology Chapter 22: Haemopoietic progenitor cells Annexe 7: Requirements for the timing of testing for HPCs
12 April	<u>CN 22-2023</u>	Annexe 3.5: Red Cells and Plasma, Leucocyte Depleted
13 February	<u>CN 06-2023</u>	Chapter 9: Microbiology tests for donors and donations: general specifications for laboratory test procedures Chapter 10: Investigation of suspected transfusion-transmitted infection Chapter 19: Tissue Banking: general principles Chapter 20: Tissue Banking: selection of donors Chapter 21: Tissue Banking: tissue retrieval and processing Annexe 6: Advanced Therapy Medicinal Products (ATMPs)

2022

22 June	<u>CN 33-2022</u>	Chapter 8: Evaluation of novel blood components, production processes and blood packs: generic protocols
22 March	<u>CN 09-2022</u>	7.5.6: Human Plasma for Fractionation, Leucocyte Depleted
02 March	<u>CN 10-2022</u>	Annexe 4: Redundant Components - Convalescent Plasma
02 March	<u>CN 11-2022</u>	Annexe 3: Provisional Components - Whole blood, leucocyte depleted, for clinical studies

02 March	<u>CN 12-2022</u>	Annexe 3: Provisional Components - Cryoprecipitate pooled, leucocyte depleted, extended shelf life post-thaw
11 January	<u>CN 44-2021</u>	Annexe 5: Blood Components for Contingency Use

2021

22 June	<u>CN 18-2021</u>	Chapter 3: - Care and selection of whole blood and component donors (including donors of pre-deposit autologous blood)
12 January	<u>CN 03-2021</u>	Chapter 21: Tissue banking: tissue retrieval and processing

2020

17 November	<u>CN 66-2020</u>	Annexe 3: Provisional Component - Convalescent Plasma (COVID-19), FFP, Leucocyte Depleted
17 November	<u>CN 67-2020</u>	Annexe 3: Provisional Component - Convalescent Plasma (COVID-19), FFP, for Neonates and Infants, Leucocyte Depleted
26 October	<u>CN 35-2020</u>	Annexe 3: Provisional Component - Whole Blood, Leucocyte Depleted for Clinical Studies
16 September	<u>CN 47-2020</u>	Annexe 5: Platelets, Apheresis, Leucocyte Depleted, at Reduced Dose as a Contingency
08 June	<u>CN 32-2020</u>	Annexe 3: Provisional Component - Red Cells and Plasma, Leucocyte Depleted
06 May	<u>CN 23-2020</u>	Chapter 7: Fresh Frozen Plasma for Neonates and Infants, Leucocyte Depleted
06 May	<u>CN 24-2020</u>	Chapter 7: Cryoprecipitate for Neonates and Infants, Leucocyte Depleted
06 May	<u>CN 25-2020</u>	Chapter 7: Fresh Frozen Plasma, Leucocyte Depleted
07 May	<u>CN 27-2020</u>	3.15: Blood Tests
21 April	<u>CN 19-2020</u>	Annexe 4: Redundant Components
21 April	<u>CN 20-2020</u>	Annexe 4: Redundant Components - Granulocytes, Apheresis
21 April	<u>CN 21-2020</u>	Annexe 5: Blood Components for Contingency Use
21 April	<u>CN 22-2020</u>	Annexe 5.1: Red Cells in Additive Solution, Leucocyte Depleted, Extended Shelf Life

2019

26 November	<u>CN 34-2020</u>	Chapter 7: Platelets in Plasma and Additive Solution for Neonatal Use, Leucocyte Depleted
-------------	-----------------------------------	---

2017

06 April	<u>CN 10-2017</u>	Chapter 7: Use of plasma from first time donors
27 January	<u>CN 01-2017</u>	Chapter 11: General guidelines for reagent red cell manufacture
27 January	<u>CN 02-2017</u>	Chapter 17 and 18 - Additional guidance re HNA and HPA antibody detection methods

2016

15 August	<u>CN 32-2016</u>	Chapter 7: Red Cells, Thawed and Washed, Leucocyte Depleted
15 August	<u>CN 33-2016</u>	Chapter 7: Removal of red cells from a controlled temperature environment
15 August	<u>CN 34-2016</u>	Chapter 7: Removal of upper limit of pH from Platelet Components
21 June	<u>CN 31-2016</u>	Annexe 3: Trial Components
11 May	<u>CN 23-2016</u>	Chapter 21: Tissue banking: Tissue retrieval and processing
01 April	<u>CN 16-2016</u>	Chapter 7: Fresh Frozen Plasma, Leucocyte Depleted
17 March	<u>CN 12-2016</u>	Chapter 9: Microbiology tests for donors and donations: general specifications for laboratory test procedures

2015

14 December	<u>CN 30-2015</u>	Chapter 7: Red Cells, Washed, Leucocyte Depleted
07 December	<u>CN 18-2015</u>	Chapter 7: Interruptions to agitation and testing of Platelets, Pooled, Buffy Coat Derived, Leucocyte Depleted and Platelets, Apheresis, Leucocyte Depleted
07 December	<u>CN 19-2015</u>	Chapter 7: Platelets in Additive Solution and Plasma, Leucocyte Depleted
07 December	<u>CN 20-2015</u>	Chapter 6: Specific gravity of blood components
07 December	<u>CN 21-2015</u>	Chapter 7: Leucocyte depletion of blood components - Concessionary release
07 December	<u>CN 22-2015</u>	Chapter 7: Concessionary Release Limits for Selected Components
07 December	<u>CN 23-2015</u>	Chapter 9: Removal of Chapter 9.4.2. and Figure 9.6
07 December	<u>CN 29-2015</u>	25.6: Table 25.5: Protocol 000001 – blood component dispatch information
21 January	<u>CN 01-2015</u>	25.6: Tables 25.4 and 25.5: Protocol 000001 – blood component dispatch information

2014

09 May	<u>CN 25-2014</u>	Chapter 5, Appendix I: Points of care
--------	-----------------------------------	---------------------------------------

2013

31 December	<u>CN 15-2013</u>	Chapter 3, Appendix I: Extra-corporeal volume tables
31 December	<u>CN 16-2013</u>	7.9.1: Platelets, Pooled, Buffy Coat Derived, Leucocyte Depleted 7.11.1: Platelets in Additive Solution and Plasma, Leucocyte Depleted 7.12.1: Platelets in Additive Solution, Leucocyte Depleted 9.5.3.1: Single-test system 12.11.2: Blood and blood components from group O donors with high titres of anti-A, anti-B and/or anti-A,B

31 December	<u>CN 17-2013</u>	7.15: Fresh Frozen Plasma, Leucocyte Depleted 7.16: Fresh Frozen Plasma, Methylene Blue Treated and Removed, Leucocyte Depleted 7.17: Cryoprecipitate, Leucocyte Depleted 7.18: Cryoprecipitate Pooled, Leucocyte Depleted 7.20: Plasma, Cryoprecipitate Depleted, Leucocyte Depleted 7.27: Fresh Frozen Plasma, Neonatal Use, Methylene Blue Treated and Removed, Leucocyte Depleted 7.28: Cryoprecipitate, Methylene Blue Treated and Removed, Leucocyte Depleted 7.33: Cryoprecipitate, Pooled, Methylene Blue Treated and Removed, Leucocyte Depleted
26 June	<u>CN 11-2013</u>	7.33: Cryoprecipitate, Pooled, Methylene Blue Treated and Removed, Leucocyte Depleted
26 June	<u>CN 12-2013</u>	Annexe 3: Platelets in Additive Solution and Plasma, Leucocyte Depleted, Pathogen-reduced